Has Martin Beerman received payments from drug or device companies?

Yes. Drug and device makers reported $2,860 in general payments to Martin Beerman across 138 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Martin Beerman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Martin Beerman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Martin Beerman

Gastroenterology · Sandusky, OHNPI 1902893639

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 34.5% of the total. Reporting peaked in 2019 at $1,842 and has fallen 74.5% since, to $469 in 2021. That places this record below the midpoint for gastroenterology clinicians in OH, where the typical reported total is $2,203.

$2,860in general payments, 2019–2025

Across 138 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$986
Gilead$540
Pfizer$373
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$289
Janssen Scientific Affairs, LLC$178
Takeda Pharmaceuticals U.S.A., Inc.$115
plus $379 from 8 others

What the payments were for

Food & beverage$2,852100%
Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	38	$986
Gilead	37	$540
Pfizer	12	$373
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	14	$289
Janssen Scientific Affairs, LLC	2	$178
Takeda Pharmaceuticals U.S.A., Inc.	11	$115
Intercept Pharmaceuticals, Inc.	5	$108
Johnson & Johnson	8	$107
UCB, Inc.	3	$51
Ferring Pharmaceuticals Inc.	3	$44
Shionogi Inc	2	$24
Daiichi Sankyo Inc.	1	$21
Nestle Healthcare Nutrition Inc.	1	$13
Vivus LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Mavyret$248
Creon$124
TRULANCE$123
XELJANZ$122
STELARA$101

How this compares

$2,860 in reported general payments places this provider in the 50th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio →

Other gastroenterology in Sandusky

Naim AlkhouriWestlake$1.9M
Pierre GholamCleveland$1.6M
Anita AfzaliCincinnati$798K
Mohamed NaemWestlake$708K
Kara de FeliceCincinnati$427K
Tasos ManokasColumbus$411K
Florian RiederCleveland$396K
Allan PeckCincinnati$391K
Dany RaadHighland Hills$387K
Stanley CohenCleveland$338K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →